Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1647
This examiner grants 22% of resolved cases
Andrea Lynne Morris Spencer has a small record of 9 resolved cases in Tech Center 1600 and Art Unit 1631. The allowance rate of 22.2% is low, indicating a challenging environment for applicants. This is paired with a median days to allowance of 1402, which is a very long pendency period. The 9 resolved cases suggest a rigorous examination process that requires significant time.
The interview lift of 35.7% is a critical figure for practitioners. Despite the low 22.2% base allowance rate, the 35.7% lift suggests that interviews are quite effective at moving cases toward a grant. For the 9 resolved cases, the data indicates that verbal interaction is a key strategy for overcoming rejections. Practitioners should prepare for the 1402 days of pendency but use the 35.7% lift to improve their odds. In Art Unit 1631, the 22.2% allowance rate makes direct engagement a necessary part of the prosecution strategy. Verbal advocacy appears to be more effective than written arguments alone in this docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18339665 | Compositions and Methods for Reducing HLA-A in a Cell | Non-Final OA | Intellia Therapeutics, Inc. |
| 18031470 | POLOXAMERS FOR CELL CULTURE | Final Rejection | MERCK PATENT GMBH |
| 17407606 | NONVIRAL GENERATION OF GENOME EDITED CHIMERIC ANTIGEN RECEPTOR T CELLS | Final Rejection | Wisconsin Alumni Research Foundation |
| 17628913 | Targeted RNA cleavage with CRISPR-Cas | Final Rejection | University of Rochester |
| 17778079 | Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof | Final Rejection | Washington University |
| 17912889 | COMPOSITIONS AND METHODS FOR ENHANCED LENTIVIRAL PRODUCTION | Final Rejection | Massachusetts Institute of Technology |
| 17700880 | GENETICALLY-EDITED IMMUNE CELLS AND METHODS OF THERAPY | Final Rejection | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17936286 | VIRAL DELIVERY OF GAS VESICLE GENES | Final Rejection | California Institute of Technology |
| 17426993 | ADENO-ASSOCIATED VIRUS DELIVERY OF CLN6 POLYNUCLEOTIDE | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18194691 | ANKYRIN-RICH BTB/POZ DOMAIN-CONTAINING PROTEIN-2 (ABTB2) FOR SUPPRESSING PANCREATIC CANCER GROWTH | Final Rejection | The Curators of the University of Missouri |
| 18040648 | NOVEL AAV CAPSIDS AND COMPOSITIONS CONTAINING SAME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17997110 | COMPOSITIONS AND METHODS FOR REDUCING NUCLEASE EXPRESSION AND OFF-TARGET ACTIVITY USING A PROMOTER WITH LOW TRANSCRIPTIONAL ACTIVITY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17278679 | EDITING OF HAEMOGLOBIN GENES | Final Rejection | Oxford University Innovation Limited |
| 18269622 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING GLYCOGEN STORAGE DISEASES | Non-Final OA | DUKE UNIVERSITY |
| 17757475 | Systems and Methods for Producing Efficacious Regulatory T Cells | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. |
| 17917188 | GENOME ENGINEERING METHOD AND GENOME ENGINEERING KIT | Final Rejection | Tokyo Institute of Technology |
| 17627210 | TRIPARTITE SYSTEMS FOR PROTEIN DIMERIZATION AND METHODS OF USE | Non-Final OA | MEDIMMUNE LIMITED |
| 18331042 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17995128 | ENHANCEMENT OF THE PRODUCTION OF ADENOVIRUS-BASED GENE TRANSFER VECTORS | Final Rejection | Greffex, Inc. |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | Final Rejection | Greffex, Inc. |
| 17778175 | THERAPEUTIC ADENO-ASSOCIATED VIRUS COMPRISING LIVER-SPECIFIC PROMOTERS FOR TREATING POMPE DISEASE AND LYSOSOMAL DISORDERS | Final Rejection | ASKLEPIOS BIOPHARMACEUTICAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy